JP2014534237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534237A5 JP2014534237A5 JP2014541298A JP2014541298A JP2014534237A5 JP 2014534237 A5 JP2014534237 A5 JP 2014534237A5 JP 2014541298 A JP2014541298 A JP 2014541298A JP 2014541298 A JP2014541298 A JP 2014541298A JP 2014534237 A5 JP2014534237 A5 JP 2014534237A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- seq
- domain
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 6
- 230000009870 specific binding Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 4
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000023732 binding proteins Human genes 0.000 claims 4
- 108091008324 binding proteins Proteins 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 229940122558 EGFR antagonist Drugs 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557939P | 2011-11-10 | 2011-11-10 | |
| US61/557,939 | 2011-11-10 | ||
| US201261609968P | 2012-03-13 | 2012-03-13 | |
| US61/609,968 | 2012-03-13 | ||
| US201261613538P | 2012-03-21 | 2012-03-21 | |
| US61/613,538 | 2012-03-21 | ||
| PCT/US2012/064311 WO2013071016A2 (en) | 2011-11-10 | 2012-11-09 | Methods of inhibiting tumor growth by antagonizing il-6 receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000818A Division JP6283754B2 (ja) | 2011-11-10 | 2017-01-06 | Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534237A JP2014534237A (ja) | 2014-12-18 |
| JP2014534237A5 true JP2014534237A5 (cg-RX-API-DMAC7.html) | 2015-10-29 |
| JP6144689B2 JP6144689B2 (ja) | 2017-06-07 |
Family
ID=47179020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541298A Active JP6144689B2 (ja) | 2011-11-10 | 2012-11-09 | Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 |
| JP2017000818A Active JP6283754B2 (ja) | 2011-11-10 | 2017-01-06 | Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 |
| JP2018011135A Withdrawn JP2018083841A (ja) | 2011-11-10 | 2018-01-26 | Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000818A Active JP6283754B2 (ja) | 2011-11-10 | 2017-01-06 | Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 |
| JP2018011135A Withdrawn JP2018083841A (ja) | 2011-11-10 | 2018-01-26 | Ｉｌ−６受容体を拮抗することにより腫瘍増殖を阻害する方法 |
Country Status (20)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| WO2015000181A1 (zh) * | 2013-07-05 | 2015-01-08 | 华博生物医药技术（上海）有限公司 | 新型重组融合蛋白及其制法和用途 |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| CN107428824A (zh) * | 2014-06-28 | 2017-12-01 | 科达制药 | Pdgf/vegf双重拮抗剂 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20180169230A1 (en) * | 2015-05-29 | 2018-06-21 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| CN110087530A (zh) | 2016-12-07 | 2019-08-02 | 普罗根尼蒂公司 | 胃肠道检测方法、装置和系统 |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| CN112203679A (zh) * | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| EP3765154A4 (en) | 2018-03-14 | 2021-11-24 | Celledit LLC | MODIFICATION OF IMMUNE CELLS TO REDUCE TOXICITY AND THEIR USES IN ADOPTIVE CELL THERAPY |
| CN108567981A (zh) * | 2018-07-17 | 2018-09-25 | 漯河医学高等专科学校 | 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用 |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CA3127669A1 (en) * | 2019-01-07 | 2020-07-16 | Hunan Siweikang Therapeutics Co. Ltd | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| KR20230150858A (ko) * | 2021-02-27 | 2023-10-31 | 엘루미넥스 바이오사이언시스 (쑤저우) 리미티드 | Il-6 수용체 및 혈관신생 인자를 표적화하는 항체 융합 단백질 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| HU218140B (hu) | 1991-04-25 | 2000-06-28 | Chugai Seiyaku Kabushiki Kaisha | Humán interleukin-6-receptorral szembeni átalakított humán antitest |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| CN1075387C (zh) | 1994-12-29 | 2001-11-28 | 中外制药株式会社 | 含有il－6拮抗剂的抗肿瘤剂的作用增强剂 |
| US5795695A (en) | 1996-09-30 | 1998-08-18 | Xerox Corporation | Recording and backing sheets containing linear and cross-linked polyester resins |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| IL146890A0 (en) * | 1999-06-08 | 2002-08-14 | Regeneron Pharma | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2001027116A2 (en) | 1999-10-07 | 2001-04-19 | Eli Lilly And Company | Condensed dihydroquinolinone derivatives for inhibiting mrp1 |
| WO2002036164A1 (en) | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| AU2004253770C1 (en) * | 2003-07-02 | 2010-04-15 | Innate Pharma | PAN-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy |
| MXPA06003768A (es) | 2003-10-17 | 2006-06-23 | Chugai Pharmaceutical Co Ltd | Agente terapeutico para el mesotelioma. |
| TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
| MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| WO2008154927A1 (en) * | 2007-06-21 | 2008-12-24 | Genmab A/S | Novel methods for treating egfr-associated tumors |
| WO2010065077A2 (en) * | 2008-11-25 | 2010-06-10 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat thrombosis |
| US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
-
2012
- 2012-11-04 JO JOP/2012/0332A patent/JO3370B1/ar active
- 2012-11-06 AR ARP120104169A patent/AR088671A1/es not_active Application Discontinuation
- 2012-11-09 KR KR1020147012146A patent/KR101718748B1/ko active Active
- 2012-11-09 AU AU2012335596A patent/AU2012335596B2/en active Active
- 2012-11-09 MY MYPI2014000968A patent/MY163953A/en unknown
- 2012-11-09 RU RU2014118739A patent/RU2648150C2/ru active
- 2012-11-09 SG SG11201401286QA patent/SG11201401286QA/en unknown
- 2012-11-09 UY UY0001034444A patent/UY34444A/es unknown
- 2012-11-09 US US13/672,923 patent/US20130122003A1/en not_active Abandoned
- 2012-11-09 CN CN201280055109.4A patent/CN103930443B/zh active Active
- 2012-11-09 CA CA2853836A patent/CA2853836C/en active Active
- 2012-11-09 TW TW106138384A patent/TW201806620A/zh unknown
- 2012-11-09 TW TW101141702A patent/TWI604852B/zh active
- 2012-11-09 MX MX2014004886A patent/MX357837B/es active IP Right Grant
- 2012-11-09 EP EP12787338.8A patent/EP2776468B1/en active Active
- 2012-11-09 TW TW105142150A patent/TW201716776A/zh unknown
- 2012-11-09 BR BR112014011211A patent/BR112014011211A2/pt not_active Application Discontinuation
- 2012-11-09 WO PCT/US2012/064311 patent/WO2013071016A2/en not_active Ceased
- 2012-11-09 JP JP2014541298A patent/JP6144689B2/ja active Active
-
2014
- 2014-04-01 IL IL231854A patent/IL231854A/en active IP Right Grant
- 2014-04-02 ZA ZA2014/02414A patent/ZA201402414B/en unknown
- 2014-04-17 IN IN2923CHN2014 patent/IN2014CN02923A/en unknown
- 2014-07-11 US US14/329,565 patent/US9409990B2/en active Active
-
2016
- 2016-07-07 US US15/204,639 patent/US20170022279A1/en not_active Abandoned
- 2016-10-30 IL IL248620A patent/IL248620A0/en unknown
-
2017
- 2017-01-06 JP JP2017000818A patent/JP6283754B2/ja active Active
-
2018
- 2018-01-26 JP JP2018011135A patent/JP2018083841A/ja not_active Withdrawn
- 2018-05-24 AU AU2018203666A patent/AU2018203666A1/en not_active Abandoned